Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 17/20 | 0.52 |
| ▸ | TPSB2 | P20231 | 8/20 | 0.38 |
| ▸ | F11 | P03951 | 7/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23241665 | 1.00 | CFD (0.52) | CFDTPSB2F11PDCD1CD274 | |
| SCHEMBL23217653 | 1.00 | CFD (0.52) | CFDTPSB2F11PDCD1CD274 | |
| SCHEMBL23217747 | 0.91 | CFD (0.56) | CFDTPSB2F11PDCD1CD274 | |
| SCHEMBL30010033 | 0.91 | CFD (0.56) | CFDTPSB2F11PDCD1CD274 | |
| SCHEMBL23217698 | 0.91 | CFD (0.63) | CFDTPSB2F11PDCD1CD274 | |
| SCHEMBL29672966 | 0.91 | CFD (0.63) | CFDTPSB2F11PDCD1CD274 | |
| SCHEMBL23240917 | 0.91 | CFD (0.63) | CFDTPSB2F11PDCD1CD274 | |
| SCHEMBL21437872 | 0.90 | CFD (0.53) | CFDTPSB2F11PDCD1CD274 | |
| SCHEMBL21437760 | 0.90 | CFD (0.64) | CFDTPSB2F11 | |
| SCHEMBL29633958 | 0.90 | CFD (0.64) | CFDTPSB2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CFD 1/4885TPSB2 594/4885F11 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.